Below is the information acquired on ABBOTT LABORATORIES LIMITED, which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 28 May 2020

Description of economic activities

Wholesale of pharmaceutical goods (NACE2 4646)

This company was established in 1937. It is engaged in the production and distribution of anaesthetic products to the armed forces during the war. It is a highly diversified healthcare company that discovers, develops, manufactures and markets products and services--from prevention and diagnosis to treatment and cure. Its registered head office is based in Maidenhead, United Kingdom.The company markets more than 70 percent of its products in 130 countries worldwide. Its principal businesses are global pharmaceuticals, medical nutrition and medical products, including diagnostics and cardiovascular devices. It is a leader in the field of anaesthesia, pain management, anti-infectives and HIV therapies. Its milestones in the United Kingdom include the introduction of several products namely: Erythrocin (erythromycin sterarate), Isoflurane, Survanta (beractant), Sevoflurane, Norvir (ritonavir), Synagis (palivizumab), Chirocaine (levobupivacaine), Reductil (sibutramine), Kaletra (lopinavir/ritonavir), Humira (adalimumab) and Zemplar IV (paricalcitol injection). Its products are distributed in Africa, Asia Pacific, Europe, Latin America/Caribbean, Middle East, North America, and South America. It has its headquarters in Maidenhead, Berkshire. Its manufacturing sites are located in Queenborough, Witney, and Dartford. Its mission is to develop breakthrough healthcare products that advance patient care for diseases with the greatest unmet medical need and to improve lives by providing cost-effective healthcare products and services. The company has one of the top ten pharmaceutical product pipelines in the world.
  • ABBOTT LABORATORIES LIMITED

  • United Kingdom of Great Britain and Northern Ireland (GB)
  • Company type: Corporate
  • Parent company: ABBOTT (UK) HOLDINGS LIMITED
  • Chief Executive Officer (CEO): Mr Neil Harris
  • CEO Total remuneration: N/A
  • Website: www.abbottlaboratories.co.uk

Financial data

Number of employees

N/A
553
516
509

Revenue *

N/A
302.944
289.978
293.387

EBIT *

N/A
8.645
7.354
-481

EBITDA *

N/A
17.453
15.413
8.52

* numbers are in millions

  • RepRisk Indicator (last month)*: N/A

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

  • EWC*: N/A

Standards and certifications

Global Reporting Initiative certification*

  • Global Reporting Initiative standards: N/A
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

  • Corporate Social Responsability:
    N/A
  • Accessibility: N/A

Policies

  • Training policy: N/A
  • Policy to protect the right to health and safety in the workplaces where the company operates: N/A
  • Policy to protect the right to health and safety in the workplaces in the supply chain: N/A
  • Diversity policy: N/A

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC:
  • D. 89/391/EEC:
  • D. 98/59/EC:
  • D. 2000/43/EC:
  • D. 2000/78/EC:
  • D. 2001/23/EC:
  • Council D. 2001/86/EC:
  • D. 2002/14/EC:
  • D. 2002/73/EC:
  • Council D. 2003/72/EC:
  • EP and Council D. 2005/56/EC:
  • D. 2009/38/EC:
  • D. 2004/25/EC:
  • D. 2011/35/EU:

Presence in main rankings

  • Global 100 Most Sustainable Corporations: N/A
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A